Impact of Infliximab Biosimilar CT-P13 Dose and Infusion Interval on Real-World Drug Survival and Effectiveness in Patients with Ankylosing Spondylitis
, Tae-Hwan Kim 2, Won Park 3, Yeong-Wook Song 4,5, Chang-Hee Suh 6, Soo-Kyoung Kim 7 and Dae-Hyun Yoo 2,8,*Round 1
Reviewer 1 Report
1.Modfication of dose or interval is beneficial; but they were modified either by increasing or decreasing them; doesn't THE DIRECTION of modification have ANY INFLUENCE AT ALL on your results ? In other words IT DOES NOT MATTER if one would increase or decrease the dose or the interval ? The only thing that counts is JUST TO MODIFY any of the two ? I mean, for instance, if one would increase the dose, one would do so because of lack of efficacy; so how can this have the same better results as if one would decrease the dose ?
2.What was/were the reason/reasons for switching ? If there was no medical reason, then it was expected that switched patients would have a lower BASDAI than naive ones (since they were not switched for medical reasons). So, you must provide reason/reasons for switching. (rows 161-164 in your text). The same way of thinking applies to your results on rows 165-169: is was expected that switched patients would differ in their BADAI scores dependent on the baseline dose (those with a higher baseline BASDAI would be started on higher doses of infliximab, because they would be more active disease patients)
Author Response
Please see the attachment
Author Response File: 
Author Response.pdf
Reviewer 2 Report
No comments!
Very well written with excellent statistical analysis!
Author Response
Thank you for your feedback on our manuscript. We are pleased that you have found it valuable.
